Faron Pharmaceuticals CEO Mark Bjalkanen and CFO Roni reviewed 2021 progress, highlighting pexmarilimab (anti-CLEVER-1) safety and early signs of clinical benefit in late-line solid tumor patients, with biomarker work (including interferon-gamma, TNF-alpha and IL-6) expected to guide future trial design. Management said dosing and biomarker analyses from the MATINS program should be consolidated by mid-year, with an FDA interaction targeted for Q3, and noted plans to initiate combination work in lung cancer and advance a CLEVER-1-positive myeloid leukemia study. The company also discussed cash runway into Q4 2022 following a €10 million debt draw and ongoing evaluation of a potential U.S. listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.